mNIS+7 and lower limb function in inotersen treatment of hereditary transthyretin‐mediated amyloidosis

INTRODUCTION: Inotersen, an antisense oligonucleotide inhibitor of transthyretin (TTR) protein production, demonstrated significant benefit versus placebo in the modified Neuropathy Impairment Score (NIS) +7 neurophysiologic tests (mNIS+7) in patients with hereditary TTR‐mediated amyloidosis (hATTR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dyck, P. James B., Kincaid, John C., Wiesman, Janice F., Polydefkis, Michael, Litchy, William J., Mauermann, Michelle L., Ackermann, Elizabeth J., Guthrie, Spencer, Pollock, Michael, Jung, Shiangtung W., Baker, Brenda F., Dyck, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Clinical Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540053/
https://www.ncbi.nlm.nih.gov/pubmed/32654212
http://dx.doi.org/10.1002/mus.27022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540053/
https://www.ncbi.nlm.nih.gov/pubmed/32654212
http://dx.doi.org/10.1002/mus.27022

Ejemplares similares